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Abstract
Background: (+)-Nootkatone (4) is a high added-value compound found in grapefruit juice. Allylic
oxidation of the sesquiterpene (+)-valencene (1) provides an attractive route to this sought-after
flavoring. So far, chemical methods to produce (+)-nootkatone (4) from (+)-valencene (1) involve
unsafe toxic compounds, whereas several biotechnological approaches applied yield large amounts
of undesirable byproducts. In the present work 125 cytochrome P450 enzymes from bacteria were
tested for regioselective oxidation of (+)-valencene (1) at allylic C2-position to produce (+)-
nootkatone (4) via cis- (2) or trans-nootkatol (3). The P450 activity was supported by the co-
expression of putidaredoxin reductase (PdR) and putidaredoxin (Pdx) from Pseudomonas putida in
Escherichia coli.
Results: Addressing the whole-cell system, the cytochrome CYP109B1 from Bacillus subtilis was
found to catalyze the oxidation of (+)-valencene (1) yielding nootkatol (2  and  3) and (+)-
nootkatone (4). However, when the in vivo biooxidation of (+)-valencene (1) with CYP109B1 was
carried out in an aqueous milieu, a number of undesired multi-oxygenated products has also been
observed accounting for approximately 35% of the total product. The formation of these
byproducts was significantly reduced when aqueous-organic two-liquid-phase systems with four
water immiscible organic solvents – isooctane, n-octane, dodecane or hexadecane – were set up,
resulting in accumulation of nootkatol (2 and 3) and (+)-nootkatone (4) of up to 97% of the total
product. The best productivity of 120 mg l-1 of desired products was achieved within 8 h in the
system comprising 10% dodecane.
Conclusion: This study demonstrates that the identification of new P450s capable of producing
valuable compounds can basically be achieved by screening of recombinant P450 libraries. The
biphasic reaction system described in this work presents an attractive way for the production of
(+)-nootkatone (4), as it is safe and can easily be controlled and scaled up.
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Background
The sesquiterpenes are a large class of terpenoid com-
pounds and common constituents of plant essential oils.
The parent sesquiterpenes are often readily available and
their oxygenation gives derivatives which are sought-after
fragrances and flavorings, pharmaceuticals or building
blocks for chemical synthesis [1]. For example, (+)-
valencene (1) is found in citrus oils and can be cheaply
obtained from oranges. Recently the valencene synthase
gene from orange has been cloned and functionally
expressed in E. coli [2,3]. The selective oxidation of (+)-
valencene (1) at allylic C2-position yields cis- (2) and
trans-nootkatol (3), which can be further oxidized to (+)-
nootkatone (4), a high added-value commercial flavoring
(Figure 1). Traditionally nootkatone is extracted from
grapefruits, and its price and availability is dependent on
the annual harvest, which is restricted to a narrow produc-
ing area and very sensitive to weather conditions. Thus,
Schematic experimental setup for the conversion of (+)-valencene (1) by CYP109B1 in a biphasic system Figure 1
Schematic experimental setup for the conversion of (+)-valencene (1) by CYP109B1 in a biphasic system. (+)-
Valencene (1) is converted to cis-nootkatol (2), trans-nootkatol (3) and (+)-nootkatone (4) by recombinant E. coli expressing 
CYP109B1, putidaredoxin reductase (PdR) and putidaredoxin (Pdx). The organic phase acts as substrate reservoir and allows 
the accumulation of the mono-oxygenated conversion products, which prevents them from overoxidation.Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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various approaches for chemical or biotechnological pro-
duction of (+)-nootkatone have been investigated in the
past years (very recently reviewed by Fraatz et al. [4]).
Chemical synthesis of (+)-nootkatone (4) from (+)-
valencene (1) has been studied with tert-butyl chromate
[5], via copper(I)-mediated oxidation by alkyl hydroper-
oxides [6] and with surface-functionalized silica sup-
ported by metal catalysts such as Co2+ and Mn2+ [7].
However, these synthetic methods are neither safe nor
environment-friendly, because they involve toxic heavy
metals or peroxides.
Biotechnological processes to achieve this oxidation have
also been designed. Recent attempts include the manufac-
turing of (+)-nootkatone (4) with green algae like Chlore-
lla or Euglena [8], fungi such as Aspergillus niger, Fusarium
culmorum [9], Mucor sp. [10,11] or the ascomycete Chaeto-
mium globosum [12]. Cell free enzymatic reactions for the
conversion of (+)-valencene (1) exploiting enzymes from
Cichorium intybus L. roots [13], lignin peroxidase [14] and
fungal laccase [15] have also been reported.
Several cytochrome P450 monooxygenases (P450s or
CYPs) have been reported to catalyze terpene oxidation
[16-21]. Cytochrome P450s belong to a superfamily of
heme b-containing proteins that accept a vast number of
organic compounds and catalyze an enormous variety of
oxidative reactions. These reactions include hydroxyla-
tion, epoxidation, heteroatom oxidation, C-C bond cleav-
age via successive hydroxylations and many other
complex reactions [22,23].
Interestingly, (+)-nootkatone (4) has been shown to
inhibit activity of some human P450s, including CYP2A6
and CYP2C19 [24]. However, given the large superfamily
of these enzymes (> 8100 sequences, http://drnel
son.utmem.edu/p450stats.Feb2008.htm) and their
diverse substrate range, it is unlikely that (+)-nootkatone
(4) will inhibit all P450s. Indeed, a recent report describes
the hydroxylation of (+)-valencene (1) by mutants of the
cytochromes P450cam  from  Pseudomonas putida and
P450BM3 from  Bacillus megaterium [25]. In both cases,
however, certain improvements are required. While the
reported P450cam-mutants demonstrated quite low activ-
ity, the P450BM3-mutants, although being active, had low
chemo- and regioselectivity and produced up to six
byproducts besides nootkatol (2 and 3) and (+)-nootka-
tone (4). Another report described a membrane-bound
plant P450 monooxygenase from Hyoscyamus muticus,
which was able to oxidize (+)-valencene (1) to nootkatol
[16]. Generally, all current biotechnological systems for
production of (+)-nootkatone (4) have in common an
unsatisfactory accumulation of the C2-oxidized com-
pounds because of low enzyme activity and/or the draw-
back of the formation of large amounts of byproducts.
In the search for new P450 monooxygenases with activity
and high regioselectivity towards (+)-valencene (1), we
screened 125 P450 enzymes from a novel recombinant
P450 library, based on about 250 bacterial cytochrome
P450 monooxygenases, co-expressed with putidaredoxin
reductase (PdR) and putidaredoxin (Pdx) in Escherichia
coli. The library contains, for example, the complete P450
complement of Streptomyces coelicolor A3(2), Bacillus subti-
lis 168, Nocardia farcinica IFM 10152 and Bradyrhizobium
japonicum USDA110. Generally, about 70% of the P450
candidates originate from actinomycetes. Construction
and application of this P450 library has recently been
reported with respect to steroid oxidation [26].
The actual screening identified CYP109B1 from Bacillus
subtilis, which catalyzed the regioselective oxidation of
(+)-valencene (1) to nootkatol (2 and 3) and (+)-nootka-
tone (4). When the whole-cell biooxidation of (+)-
valencene (1) with E. coli expressing CYP109B1 and elec-
tron transfer partners was carried out in an aqueous
milieu, a number of undesired multi-oxygenated oxida-
tion products was observed. In order to reduce byproduct-
formation biphasic systems with water immiscible
organic solvents were applied and the best system was
scaled-up.
Results and discussion
Screening of the recombinant P450 library
In our approach to find new P450s capable to oxidize (+)-
valencene (1) regioselectively at allylic C2-position, 125
bacterial P450s from an E. coli-based recombinant P450
library were screened. Generally, P450 monooxygenases
require electron transfer partners for activity. Since natural
electron transfer partners for most of these 125 P450s are
unknown, PdR and Pdx from P. putida were co-expressed
in the E. coli cells. In the screening two enzymes were
found to be able to oxidize (+)-valencene (1), namely
CYP109B1 from B. subtilis 168 and CYP105 from Non-
omuraea recticatena NBRC 14525 (also referred to as
P450MoxA [27]). The conversion of (+)-valencene (1) by
CYP109B1 from B. subtilis resulted in six oxidation prod-
ucts, with the desired mono-oxygenated compounds
nootkatol (2 and 3) and (+)-nootkatone (4) accounting
for approximately 65% of the total product, whereas oxi-
dation of (+)-valencene (1) by P450MoxA yielded 15 dif-
ferent mono- and multi-oxygenated oxidation products
(which mostly could not be identified), with the desired
products accounting for less than 10% of the total product
(Figure 2). The E. coli BL21(DE3) cells expressing onlyMicrobial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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PdR and Pdx did not convert (+)-valencene. Because of its
high regioselectivity, CYP109B1 was chosen as biocatalyst
for further studies.
Biooxidation of (+)-valencene by CYP109B1 in an aqueous 
system
Whole-cell biotransformation with E. coli BL21(DE3)
cells expressing PdR-, Pdx- and CYP109B1 was first carried
out in aqueous milieu (CV2 buffer, see Material and
Methods). The average expression level of CYP109B1 ver-
ified through CO-difference spectra was 160 mg l-1, which
corresponds to 7.6 mg g-1 cell wet weight (cww). Since in
all experiments 70 g cww l-1 were used, the final P450 con-
centration was approximately 530 μg ml-1. Expression of
PdR and Pdx was verified by sodium dodecyl sulphate
polyacrylamid gel electrophoresis (SDS-PAGE) [see Addi-
tional file 1].
When (+)-valencene (1) was added directly to the cell sus-
pension, the oxidation of the substrate by CYP109B1 pro-
ceeded with 270 nM min-1 and after 8 h 6% conversion
was achieved. Because of the low conversion, 2% dime-
thyl sulfoxid (DMSO) was added to the reaction. DMSO
increases the solubility of (+)-valencene (1), which is
poorly soluble in the aqueous reaction medium. In conse-
quence the volumetric productivity could be increased up
to 990 nM min-1 and after 8 h 25% of the substrate was
converted.
Electron transfer to CYP109B1 in E. coli cells can occur
either via co-expressed heterologuos PdR and Pdx and/or
via endogenous flavo- or ferredoxins and reductases from
the host strain. To investigate, if co-expressed PdR and Pdx
in fact support the activity of CYP109B1, E. coli
BL21(DE3) was transformed with the pET28a-CYP109B1-
plasmid comprising exclusively the CYP109B1-gene with-
out PdR and Pdx (see Material and Methods section). In
this case the biooxidation of (+)-valencene (1) preceded
with only 40 nM min-1, regardless of the addition of
DMSO, which demonstrates that co-expression of PdR
and Pdx is necessary for activity of CYP109B1 in vivo.
For further evaluation of the electron transport to
CYP109B1 via PdR and Pdx, a reconstituted in vitro system
GC diagrams of extracts of (+)-valencene (1) conversions Figure 2
GC diagrams of extracts of (+)-valencene (1) conversions. Conversion of 2 mM (+)-valencene (1) was carried out with 
recombinant E. coli expressing PdR, Pdx and either P450MoxA or CYP109B1 in 2 ml aqueous CV2 buffer with 2% DMSO for 8 
h at 30°C and extracted with ethyl acetate. Numbered peaks represent cis-nootkatol (2), trans-nootkatol (3), (+)-nootkatone 
(4) and overoxidation products (5, 6 and 7). * Conversion products of (+)-valencene (1) that could not be identified. ** Non-
specific peaks that were also present in the negative control.Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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with recombinantly expressed and purified CYP109B1,
PdR and Pdx [see Additional file 1] was set up as described
in the material and methods section. In this system, the
NADH oxidation rate was 64 nmol nmol-1 P450 min-1
and approximately 10% conversion of 200 μM (+)-
valencene (1) was observed, however, only if all three pro-
teins were added to the reaction mixture. Mixtures with-
out PdR and/or Pdx did not show any activity towards (+)-
valencene (1) (data not shown). Detailed biochemical
characterization of CYP109B1 is a topic of our current
investigations.
Gas chromatography (GC) analysis of reaction mixtures
after the in vivo (+)-valencene (1) biotransformation
revealed several new peaks besides the substrate peak (Fig-
ure 2). According to their mass fragmentation spectra
(MS) and by comparison with authentic reference com-
pounds three peaks were identified as cis-nootkatol (2)
(retention time [RT] = 9.9 min), trans-nootkatol (3) (RT =
10.1 min) and nootkatone (4) (RT = 11.3 min) account-
ing for 6.2, 55.1 and 4.0% of the total product, respec-
tively. Three other products were observed at RTs of 12.1,
12.3 and 13.3 min accounting for 2.3, 27.2 and 5.2% of
the total product. A time course of the reaction demon-
strated that these byproducts appeared shortly after the
two nootkatol-isomers (2 and 3) and nootkatone (4) were
formed, which indicates that these compounds could rep-
resent products of overoxidation (data not shown). Fur-
thermore, the fragmentation spectra and molecular
weights of these compounds indicated the incorporation
of two oxygen atoms into (+)-valencene (1) [see Addi-
tional file 2]. In a control experiment with nootkatone (4)
as substrate instead of (+)-valencene (1), only the product
with a RT of 13.3 min was identified by GC/MS analysis
(data not shown). Obviously, this product is the oxidized
nootkatone. Accordingly, when a mixture of nootkatol
isomers (2 and 3) was added as substrate, the products
with RT of 12.1 and 12.3 min and small amounts of (+)-
nootkatone (4) were observed. Thus these products were
assumed to be products of further oxidation of the two
nootkatol isomers (2 and 3), which is in agreement with
their MS data. In order to investigate if the primary oxida-
tion products could be protected from overoxidation, we
applied an aqueous-organic two-liquid-phase approach as
shown in figure 1.
Remarkably, in the control experiment with nootkatone
(4) instead of (+)-valencene (1), CYP109B1 oxidized
approximately 60% of (+)-nootkatone (4) (final concen-
tration 2 mM) within 2 h of conversion, whereas (+)-
valencene (1) (final concentration 2 mM) was oxidized by
only approximately 5% within this time. This means that
nootkatone is actually a better substrate for CYP109B1
than valencene. Interestingly, this phenomena has also
been reported for the P450BM3 wild type enzyme and
mutants, which accept nootkatone as substrate much bet-
ter than valencene [25].
Biocompatibility of organic solvents
Aqueous-organic two-liquid-phase systems (further
referred to as biphasic systems) represent a powerful bio-
technological tool for biotransformations of toxic organic
compounds [28-30]. This approach allows 1) the use of
high overall concentrations of hydrophobic toxic sub-
strates by regulating substrate and product concentrations
in the aqueous biocatalyst phase, and 2) simple in situ
product recovery into organic phase. Four water-immisci-
ble organic solvents (n-octane, isooctane, dodecane and
hexadecane) were chosen to set up biphasic systems and
compared to the aqueous system. Control experiments
showed that none of the organic solvents was oxidized by
the host strain.
It is known that some organic solvents used as a second
phase can damage the microbial cells [31]. Viability assays
conducted after 8 h of (+)-valencene (1) conversion with
E. coli expressing PdR, Pdx and CYP109B1 in systems with
20% (v/v) solvent showed that isooctane and octane had
a strong effect on cell viability, with only 20% of cells sur-
viving, whereas the more hydrophobic solvents dodecane
and hexadecane were totally biocompatible with E. coli, as
they did not harm the cell viability considerably. The
addition of 2% DMSO had no considerable effect on cell
viability in aqueous systems and in systems with
dodecane or hexadecane, but led to further diminution of
cell viability with octane and isooctane (Figure 3).
Biooxidation of (+)-valencene (1) in biphasic systems
First, biphasic systems without addition of DMSO were
set up. In these systems, however, the volumetric produc-
tivities were low (≤ 100 nM min-1) and after 8 h only 2%
or less (+)-valencene (1) conversion was achieved in all
systems tested. Presumably, the substrate holding capacity
of the organic solvents was too high, preventing its oxida-
tion in the aqueous phase. High distribution coefficients
(log D) measured for (+)-valencene (1) in all four organic
solvents confirm this observation (Table 1).
After addition of 2% DMSO the conversion of (+)-
valencene (1) rose significantly in all biphasic systems
employed, but was still lower in comparison to the aque-
ous system where 25% conversion was reached (Table 2).
Generally, the addition of an organic phase led to a strong
reduction of the generated multi-oxygenated byproducts
causing a shift of the product distribution towards the
mono-oxygenated compounds nootkatol (2 and 3) and
(+)-nootkatone (4) (Table 2). Moreover, the amount of
byproducts decreased with increasing amounts of organic
solvents from 10 to 20%. This tendency was similar for all
four solvents tested. Basically, addition of 10% organicMicrobial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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solvent reduced the amount of byproducts to less than
12% of the total product; 20% organic phase resulted in
less than 7% byproducts. The best result in terms of reduc-
tion of byproducts was achieved with 20% hexadecane,
were nootkatol (2  and  3) and (+)-nootkatone (4)
accounted for 97% of the total product (Figure 4).
Generally, the volumetric productivities of the biphasic
systems were lower than those of the aqueous system (990
nM min-1). For example, addition of 10% of isooctane
resulted in a 60% loss in original volumetric productivity
(400 nM min-1), 20% of isooctane – in an almost 70%
loss (Table 2). This high reduction is obviously due to the
toxicity of isooctane to E. coli, as described in the previous
section. For n-octane – which is toxic for E. coli as well –
volumetric productivities of 770 and 502 nM min-1 were
obtained at 10% or 20% n-octane, respectively. Dodecane
had the slightest effect on volumetric productivity; about
87% could be retained in the system with 10% dodecane
after 8 h conversion (860 nM min-1). Interestingly, the
retained volumetric productivities with hexadecane were
significantly lower then those observed in the presence of
n-octane, especially at 20% (Table 2), although the viabil-
ity assay demonstrated that hexadecane is benign for E.
coli.
When we determined the log D  of (+)-valencene (1),
trans-nootkatol (3) and (+)-nootkatone (4) for the bipha-
sic systems with 20% organic solvent in the presence of
2% DMSO (Table 1), in the biphasic system with hexade-
cane a log D of 0.62 for (+)-valencene (1) was obtained,
which is two-fold higher than with dodecane (0.32) and
3.5-times higher than with n-octane (0.18). The high log
D for hexadecane implies a larger substrate holding capac-
ity of this solvent, which might explain the significantly
reduced volumetric productivity of the whole-cell process
for this solvent compared to dodecane. The highest log D
for (+)-valencene under these conditions was determined
in isooctane (0.87), presumably also contributing to the
low volumetric productivities in addition to the toxicity of
this solvent.
Taking into account both, the reduction of byproduct for-
mation and volumetric productivities, the best perform-
ance was observed in the biphasic system comprising 10%
dodecane and 2% DMSO.
Reaction scale-up
Conversion of (+)-valencene (1) was carried out in 20 ml
volume for the biphasic system comprising 10%
dodecane and 2% DMSO. The influence of cell density
and substrate concentration on the yield of nootkatol (2
and 3) and (+)-nootkatone (4) was investigated.
At a constant cww of 70 g l-1 (corresponding to 18.4 g l-1
cell dry weight (cdw)) higher substrate concentrations
resulted, as expected, in higher overall amounts of desired
products, however the substrate conversion values
decreased (Table 3). For example, from 409 mg l-1 (+)-
valencene (1) 61.6 mg l-1 nootkatol (2 and 3) and (+)-
nootkatone (4) were produced, and from 818 mg l-1 (+)-
valencene (1) – 96.0 mg l-1 (Table 3). Product distribution
did not change, independently on substrate concentra-
tion.
At a constant substrate concentration of 409 mg l-1 and
two-fold increased cell density (140 g l-1) the yield of
desired products could be increased from 61.6 mg to 89.1
mg l-1. A four-fold higher cell density resulted in 94.2 mg
l-1 (Table 3). Thus, higher cell densities at a constant sub-
strate concentration lead to higher substrate conversion
and higher overall amounts of nootkatol (2 and 3) and
(+)-nootkatone (4), but lower product yields per g of cells.
Under optimized reaction conditions 120 mg l-1  of
desired products were produced. In comparison, the con-
Cell viability of E. coli Figure 3
Cell viability of E. coli. Cell viability of recombinant E. coli 
expressing PdR, Pdx and CYP109B1 was measured after 8 h 
exposure to biphasic systems consisting of CV2 buffer with 
or without 2% DMSO and 20% (v/v) organic solvents and 
compared to pure CV2 buffer (aqueous). Values represent 
mean ± standard deviation.Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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centration of desired products in the aqueous system
under the same conditions reached 83 mg l-1.
Conclusion
It was demonstrated that the identification of new P450s
capable of producing valuable compounds can basically
be achieved by the screening of recombinant P450 librar-
ies. The P450-library used in this study is easy to handle
and allows high throughput screening of various sub-
strates.
For the biooxidation of (+)-valencene (1) with E. coli
expressing recombinant CYP109B1 from Bacillus subtilis,
Pdx and PdR the use of organic solvents improved the
accumulation of nootkatol (2 and 3) and (+)-nootkatone
(4). Although the addition of organic solvents reduced the
volumetric productivity of the whole-cell process, the pro-
duction of nootkatol is promising. Considering the accu-
mulation of nootkatol (2 and 3) it should be noted that a
bottleneck reaction seems to be the oxidation of nootka-
tol (2 and 3) to (+)-nootkatone (4). Here both, process
and enzyme engineering could help to overcome this lim-
itation. For example, CYP109B1 could be optimized for
higher affinity and activity towards (+)-valencene (1) and
nootkatol (2 and 3) with the goal to achieve an increased
productivities of the whole-cell process and higher
amounts of (+)-nootkatone (4). Alternatively, a specific
dehydrogenase could be expressed in the same E. coli host
to oxidize nootkatol (2 and 3) to (+)-nootkatone (4) and
thereby regenerate NADH, which in addition would
reduce metabolic stress for the host strain.
Methods
Enzymes and materials
Restriction endonucleases, T4 DNA ligase, Pfu  DNA
polymerase and isopropyl β-D-thiogalactopyranoside
(IPTG) were obtained from Fermentas (St. Leon-Rot, Ger-
many). (+)-Valencene and (+)-nootkatone were from
Table 1: Distribution coefficients for (+)-valencene (1), trans-nootkatol (3) and (+)-nootkatone (4)
Compound DMSO [%]a Distribution coefficient (log D)b
isooctane n-octane dodecane hexadecane
(+)-valencene (1) 0 2.79 ± 0.03 2.61 ± 0.04 2.74 ± 0.05 2.62 ± 0.10
trans-nootkatol (3) 0 2.43 ± 0.03 2.31 ± 0.04 2.12 ± 0.02 2.11 ± 0.04
(+)-nootkatone (4) 0 2.63 ± 0.04 2.55 ± 0.03 2,68 ± 0.08 2.37 ± 0.12
(+)-valencene (1) 2 0.87 ± 0.05 0.18 ± 0,03 0.32 ± 0.08 0.62 ± 0.02
trans-nootkatol (3) 2 1.55 ± 0.05 1.57 ± 0.05 1.39 ± 0.06 1.23 ± 0.04
(+)-nootkatone (4) 2 1.77 ± 0.04 1.98 ± 0.05 1.83 ± 0.07 1.29 ± 0.06
aFinal concentration in the mixture.
bValues represent mean ± standard deviation.















aqueous 6.2 55.1 4.0 2.3 27.2 5.2 24.7 ± 3.8 990 ± 158
10% dodecane 7.4 82.8 2.6 --- 6.1 1.1 19.5 ± 2.9 859 ± 121
20% dodecane 7.6 85.6 2.7 --- 3.9 0.2 17.2 ± 1.8 719 ± 75
10% n-octane 7.7 80.2 3.2 0.4 7.3 1.2 16.4 ± 2.7 770 ± 116
20% n-octane 8.5 81.3 3.8 --- 5.3 1.1 14.4 ± 2.4 502 ± 101
10% isooctane 10.1 74.9 4.1 0.1 8.5 2.3 9.6 ± 1.6 399 ± 68
20% isooctane 11.3 78.3 4.5 --- 4.6 1.3 7.8 ± 1.8 313 ± 84
10% 
hexadecane
10.8 80.4 2.8 --- 5.3 0.7 15.1 ± 3.5 631 ± 150
20% 
hexadecane
12.6 81.7 3.0 --- 2.7 --- 9.3 ± 1.2 387 ± 53
aConversion of 2 mM (+)-valencene (1) was carried out with recombinant E. coli expressing PdR, Pdx and CYP109B1 in 2 ml CV2 buffer with 2% 
DMSO for 8 h at 30°C and extracted with ethyl acetate. All values are shown as mean (± standard deviation), n ≥ 3.
bValues are given in % of the total product.
cPercental amount of (+)-valencene (1) that was converted to products.
RT: Retention time during GC (for unidentified products).
---: Compound was not observed in the reaction. The detection limit was 4 μM.Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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Fluka (Buchs, Switzerland). Glucose-6-phosphate dehy-
drogenase from Leuconostoc mesenteroides (EC 1.1.1.49)
and other chemicals, solvents and buffer components
were purchased from Sigma-Aldrich (Schnelldorf, Ger-
many).
Molecular biological techniques
General molecular biology manipulations and microbio-
logical experiments were carried out by standard methods
[32]. Construction of pT7-camAB – a plasmid based on
pET11a (Novagen, Darmstadt, Germany) and harboring
the camA (PdR) and camB (Pdx) genes from Pseudomonas
putida ATCC 17453 – has been described previously [33].
pT7NS-camAB was prepared by insertion of an NdeI-SpeI
linker into pT7-camAB and plasmids for the expression of
bacterial P450s were created by amplification of anno-
tated P450-encoding genes from genomic DNA of various
bacteria as described in [33]. The plasmid for co-expres-
sion of PdR, Pdx and CYP109B1 – pCYP109B1-camAB –
was constructed by amplification of the CYP109B1-
encoding yjiB-gene [GenBank:CAB13078] from genomic
DNA of the Bacillus subtilis strain 168 [34] and by follow-
ing ligation of the PCR fragment into pT7NS-camAB uti-
lizing the restriction sites for NdeI and SpeI of the NdeI-
SpeI linker. pCYP109B1-camAB comprises the genes
under control of the IPTG-inducible T7 phage-promoter
in an artificial operon in the following order: yjib
(CYP109B1), camA (PdR), camB (Pdx).
pET28a-CYP109B1 – a vector for the expression of
CYP109B1 alone, without PdR and Pdx – was constructed
as follows: The yjiB-gene was amplified from pCYP109B1-
camAB with the primers 5'-AATAgctagcATGAATGTGT-
TAAACCGCCG-3' and 5'-TCGctcgagTTACATTT-
TCACACGGAAGC-3'. The PCR was performed with Pfu
DNA polymerase under the following conditions: 95°C
for 4 min, 25 cycles of (95°C for 1 min, 56°C for 30 s,
72°C for 3 min), 72°C for 5 min. The PCR-product was
purified, digested with endonucleases NheI and XhoI and
inserted into the previously linearized expression vector
pET28a(+) (Novagen, Darmstadt, Germany). The result-
ing DNA-construct encoded for N-terminally His6-tagged
CYP109B1 under control of the IPTG-inducible T7 phage-
promoter.
pET28a-camA – a vector for the expression of PdR – was
constructed by PCR-amplification of the camA-gene from
pT7NS-camAB with the primers 5'-GGAATTCCATAT-
GAACGCAAACGAC-3' and 5'-GATCGAATTCTCAG-
GCACTACTCAG-3'. The PCR was done as described for
pET28a-CYP109B1, the PCR-product was purified and
digested with endonucleases NdeI and EcoRI and inserted
into previously linearized expression vector pET28a(+).
The resulting plasmid encoded for N-terminally His6-
tagged PdR under control of the IPTG-inducible T7 phage-
promoter.
The basic steps for the design of pET28a-camB – which
incorporates the camB-gene under control of the IPTG-
inducible T7 phage-promoter for expression of N-termi-
nal His-tagged Pdx – were identical to those for construc-
tion of pET28a-camA, except for primers. The primers 5'-
GGGAATTCCATATGTCTAAAGTAGTGTAT-3' and 5'-
CCGGAATTCTTACCATTGCCTATCGGG-3' were used for
PCR in this case.
Protein expression and purification
Recombinant CYP109B1 was expressed under the follow-
ing conditions: E. coli BL21(DE3) cells were transformed
with pET28a-CYP109B1 and transformants were selected
on LB-agar plates with kanamycin (30 μg ml-1). 400 ml LB
supplemented with 30 μg ml-1 of kanamycin were than
inoculated with 2 ml overnight culture – grown from a
single colony – and grown at 37°C and 180 rpm, until the
optical density at 600 nm (OD600) reached approximately
1.0. 100 μM IPTG, 80 μg ml-1 5-aminolevulinic acid and
0.1 μM FeSO4 were added and the culture was grown for
another 19 h at 30°C and 140 rpm. Cells were harvested
by centrifugation at 10,000 × g for 20 min, the superna-
tant was discarded and the cell pellet was resuspended in
Product distributions of (+)-valencene (1) conversions in  biphasic systems Figure 4
Product distributions of (+)-valencene (1) conver-
sions in biphasic systems. Conversion of 2 mM (+)-
valencene (1) was carried out with recombinant E. coli 
expressing PdR, Pdx and CYP109B1 in biphasic systems con-
sisting of 2 ml CV2 buffer, 2% DMSO and organic solvents (v/
v) as indicated for 8 h at 30°C and extracted with ethyl ace-
tate. Values represent mean ± standard deviation, n ≥ 3. 
"Products" sum up the percental amounts of the total prod-
uct of the two nootkatol isomers (2 and 3) and (+)-nootka-
tone (4), "byproducts" combine the percental amounts of the 
total product of the compounds with RT 12.1, 12.3 and 13.3 
min, respectively.Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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10 ml purification buffer (50 mM TrisHCl, pH 7.5, 500
mM NaCl, 100 μM phenylmethanesulfonyl fluoride).
Cells were lysed by sonification on ice (3× 1,5 min, 1 min
intermission), cell debris was removed by centrifugation
(35,000 × g, 30 min, 4°C), the soluble protein fraction
was recovered and filtered through a 0,2 μm filter.
Recombinant expression of PdR and Pdx was achieved by
transformation of E. coli BL21(DE3) with either pET28a-
camA or pET28a-camB. Transformants were selected on
LB-agar plates with kanamycin (30 μg ml-1). 400 ml LB
with kanamycin were inoculated with 2 ml from an over-
night culture – grown from a single colony – and grown at
37°C and 180 rpm, until the OD600 reached approxi-
mately 0.7. 100 μM IPTG were added and the culture was
grown for 17 h at 25°C and 160 rpm. The soluble protein
fraction was recovered as described for CYP109B1.
Purification of CYP109B1, PdR and Pdx was done by
immobilized metal affinity chromatography (IMAC) with
a Talon® resin (7 ml bed volume). Protein lysates were
applied to the column, which was pre-equilibrated with 5
column volumes of purification buffer. Non-specifically
bound proteins were washed from the column with 4 col-
umn volumes of purification buffer with 5 mM imidazol,
before the bound protein was eluted with purification
buffer containing 100 mM imidazol. 5% Glycerol was
added to the eluate and it was dialyzed two times against
2 l of 50 mM TrisHCl, pH 7.5, containing 5% glycerol,
100 μM phenylmethanesulfonyl fluoride and frozen at -
20°C until use.
Determination of protein concentration
The P450 expression levels were estimated using the CO-
difference spectral assay as described previously [35,36]
using ε450–490 = 91 mM-1 cm-1.
The concentration of PdR was determined as the average
of the concentration calculated from each of the three
wavelength 378, 454 and 480 nm using extinction coeffi-
cients 9.7, 10.0 and 8.5 mM-1 cm-1 [37].
The concentration of Pdx was determined as the average
concentration calculated from the two wavelength 415
and 455 nm using extinction coefficients 11.1 and 10.4
mM-1 cm-1 [37].
In vitro activity reconstitution of CYP109B1
A reconstituted in vitro system for conversion of (+)-
valencene (1) by CYP109B1 was set up as described in
[25] except for addition of catalase. The components were
mixed in a 1,5 ml reaction tube, incubated at 30°C for 2
min and 200 μM NADH were added. Absorption at 340
nm was followed spectro-photometrical and NADH-con-
sumption was calculated using ε = 6.22 mM-1 cm-1. For
product identification the setup was slightly modified as
follows: 1 μM PdR, 10 μM Pdx, 1 μM CYP109B1, 5 units
of glucose-6-phosphate dehydrogenase, 4 mM glucose-6-
phosphat and 1 mM MgCl2. After incubation, the internal
standard (-)-carvone (50 μM) was added, samples were
extracted with 400 μl ethyl acetate and the extracts were
analyzed by GC/MS.
Construction of whole-cell biocatalysts
E. coli BL21(DE3) was used as a host for the gene expres-
sion. The BL21(DE3) cells were correspondingly trans-
formed with plasmids harboring P450-genes and grown
in 50 ml of M9 expression-medium, which is based on M9
medium [32], supplemented with 1% casamino acids, 20
μg ml-1 thymine, 0.1 μM FeSO4, 80 μg ml-1 5-aminole-
vulinic acid and 50 μg ml-1 carbenicillin. For protein
expression the Overnight Express™ Autoinduction System
1 (Novagen, Darmstadt, Germany) was added according
to the supplier's manual. The cultivation was carried out
for 24 h at 25°C. Cells were collected by centrifugation
(2400 × g) and resuspended in 10 ml of aqueous CV2
buffer (50 mM potassium phosphate, pH 7.5, 2% glyc-
erol, 0.1 mM IPTG, 50 μg ml-1 carbenicillin), whereupon
the cww was adjusted to 70 g l-1. The substrate was added
to a final concentration of 2 mM for the biooxidation
assay either directly or from a stock solution dissolved in
DMSO to yield a final DMSO concentration in the reac-
tion mixture of 2%. Samples were then split in 2 ml aliq-
Table 3: Yields of nootkatol (2 and 3) and (+)-nootkatone (4) in biphasic systems with 10% dodecanea
Cww [g l-1]c valencene [mg l-1] Conversion [%]b Yield [mg g-1 cdw] Yield [mg l-1]
70 409 15.1 3.35 61.6
70 613 13.2 4.40 80.9
70 818 11.8 5.22 96.0
140 409 21.8 2.42 89.1
280 409 23.0 1.28 94.2
140 818 14.1 3.14 118.5
aConversion of (+)-valencene (1) was carried out with recombinant E. coli expressing PdR, Pdx and CYP109B1 in 20 ml CV2 buffer with 2% DMSO 
for 8 h at 30°C and extracted with ethyl acetate. Cell wet weight (cww) was as indicated; 70 g cww correspond to 18.4 g cell dry weight (cdw). 
Values are shown as mean of two experiments.
bPercental amount of (+)-valencene (1) that was converted to nootkatol (2 and 3) and (+)-nootkatone (4)Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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uots. For the biphasic systems 10 or 20% (v/v) of an
organic solvent (isooctane, n-octane, dodecane or hexade-
cane) was added to the CV2 buffer. The biotransformation
was carried out at 30°C under shaking at 200 rpm for 8 h.
After incubation the internal standard (-)-carvone (50
μM) was added and samples were extracted with 1 ml of
ethyl acetate for GC or GC/MS analysis. A negative control
was performed with E. coli BL21(DE3) transformed with
pT7NS-camAB.
For biooxidation reactions on a larger scale, 20 ml of CV2
buffer were set up with 70, 140 or 280 gcww l-1 in round
bottom flasks (70 g cww correspond to 18.4 g cdw). (+)-
Valencene (1) was added from concentrated stock solu-
tions in DMSO to achieve final concentrations of 2, 3 or 4
mM (+)-valencene (1) and 2% DMSO in the reaction mix-
ture. The reaction was carried out at 30°C for 8 h under
stirring with a magnetic stirrer. After incubation the inter-
nal standard (-)-carvone (50 μM) was added and samples
were extracted with 10 ml ethyl acetate for GC analysis.
Viability assays
E. coli viability during the biotransformation was moni-
tored by taking cell aliquots from the reaction mixtures at
certain time points. 40 μl of the aqueous phase were
diluted in serial dilutions, plated on Luria broth agar
plates containing ampicillin (100 μg ml-1) and after incu-
bation at 30°C for 24 h the grown colonies were counted.
Product analysis
The concentrations of (+)-valencene (1) and its conver-
sion to products was determined by GC analysis using a
GC2014 (Shimadzu, Kyoto, Japan) equipped with an
Equity-5 column (30 m × 0.25 mm × 0.25 μm, Supelco,
Pennsylvania, USA). The injector and detector tempera-
tures were set at 250 and 270°C, respectively. 1 μl of a
sample was injected at a split ratio of 4, with helium as
carrier gas. The column temperature was maintained at
120°C for 4 min, ramped to 250°C at a rate of 10°C min-
1 and held at 250°C for 5 min. For quantitative GC analy-
sis the FID response was calibrated for (+)-valencene (1)
and (+)-nootkatone (4). Mixtures of CV2 buffer contain-
ing (+)-valencene (1) or (+)-nootkatone (4) in final con-
centrations of 50 to 2500 μM and (-)-carvone from a 5
mM stock solution in ethanol (final concentration 50 μM)
as an internal standard were extracted with 1 ml of ethyl
acetate and analyzed as described. The ratio of the area of
the substrate to that of the internal standard was plotted
against the substrate concentration to give a straight-line
calibration plot.
Mass spectra were acquired on a GC/MS-QP2010 (Shi-
madzu) equipped with a FS-Supreme-5 column (30 m ×
0.25 mm × 0.25 μm, Chromatographie Service GmbH,
Langerwehe, Germany). The same setup as for the GC-
analysis was used. The products were identified by their
characteristic mass fragmentation patterns by comparison
with mass spectra of authentic reference compounds and
by comparison with mass spectra reported elsewhere [16].
Determination of distribution coefficients
The distribution coefficients (log D) for (+)-valencene (1),
trans-nootkatol (3) and (+)-nootkatone (4) were deter-
mined by dissolving increasing amounts of the respective
compound (final concentration 500 to 5000 μM) in a
50% (v/v) mixture of aqueous CV2 buffer and an organic
solvent (isooctane, n-octane, dodecane or hexadecane) in
a total volume of 10 ml. After equilibration for 4 h at
25°C under vigorous shaking, phases were separated by
centrifugation. 500 μl of each the organic and the aqueous
phase were recovered separately and the internal standard
(-)-carvone (final concentration 50 μM) was added. The
aqueous phase was extracted with 1 ml of ethyl acetate
and 500 μl of ethyl acetate were added to the organic
phase. Both phases were analyzed quantitatively by GC.
Subsequently the log D values were calculated.
Synthesis of cis- (2) and trans-nootkatol (3)
390 mg (+)-nootkatone (4) was dissolved in 2 ml dry die-
thyl ether and added dropwise under stirring at 0°C on ice
to a suspension of 130 mg LiAlH4 in 8 ml dry diethyl
ether. After complete conversion, the solution was cooled
down to -30°C and 20 ml saturated sodium potassium
tartrate solution were added. The solution was allowed to
warm to ambient temperature and was stirred for 16 h.
The aqueous phase was extracted with diethyl ether (4 ×
20 ml). The extracts were combined and dried over anhy-
drous MgSO4. Solvents were removed at 40°C. The raw
product was applied to a silica gel column (ethyl ace-
tate:petroleum ether 1:10). Fractions were analyzed by
GC/MS and NMR. Nootkatol was isolated as a mixture of
cis- (2) and trans-nootkatol (3) with a ratio of cis:trans of
approximately 1:9. Solvents were removed from the noot-
katol fraction at 40°C until no change in mass occurred.
Nootkatol (2 and 3) (350 mg, 89%) was retained as color-
less oil.
1H-NMR (500 MHz, CDCl3, for numbering see figure 1):
δ = 0.89 (3 H, d, J 6.9, 4-Me), 0.95 (1 H, br s, 2-OH), 1.00
(3 H, s, 5-Me), 1.21 (1 H, dddd, J 13.9, 12.4, 12.4, 4.3, 8-
Hax), 1.37 (1 H, ddd, J 12.7, 12.7, 10.0, 3-Hax), 1.52 (1 H,
dqd, J 13.0, 6.8, 2.1, 4-H), 1.71 (3 H, dd, J 1.3, 1.1, 13-
Me), 1.77 (1 H, dddd, J 12.3, 2.3, 1.6, 1.3, 8-Heq), 1.78 –
1.84 (1 H, m, 3-Heq), 1.86 (1 H, ddd, J 12.8, 2.7, 2.7, 6-
Heq), 2.12 (1 H, ddd, J 14.1, 4.2, 2.6, 9-Heq), 2.21 – 2.28
(1 H, m, 9-Hax), 2.29 – 2.37 (1 H, m, 7-H), 4.23 – 4.27 (1
H, m, 2-Hax), 4.67 – 4.70 (2 H, m, 2× 14-Hax), 5.32 (1 H,
ddd, J 2.6, 1.8, 1.8, 1-Hax) ppm.Microbial Cell Factories 2009, 8:36 http://www.microbialcellfactories.com/content/8/1/36
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13C-NMR (500 MHz, CDCl3): δ = 15.4 (4-Me), 18.2 (5-
Me), 20.8 (13-Me), 32.4 (C-8), 32.9 (C-6), 37.3 (C-10),
38.2 (C-5), 39.3 (C-4), 40.8 (C-7), 44.6 (C-9), 68.0 (C-2),
108.6 (C-14), 124.3 (C-1), 146.1 (C-10), 150.2 (C-13)
ppm.
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